Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 15 BIIB Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15 PFE Pfizer: Best Trading Momentum Since 2021 And 6% Yield
May 15 BIIB Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy
May 15 PFE 3 No-Brainer Stocks to Buy With $500 Right Now
May 15 BIIB UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 BIIB Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14 BIIB Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
May 14 PFE 2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
May 14 SILO Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14 PFE NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
May 13 BIIB 15 Most Depressed States in the US
May 13 PFE Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
May 13 ACIU Sector Update: Health Care Stocks Mixed Late Afternoon
May 13 ACIU Top Midday Gainers
May 13 PFE AstraZeneca, Pfizer to invest combined $900M+ in France for R&D, production
May 13 ACIU Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13 PFE One stock is dragging down the S&P 500's earnings growth
May 13 DNLI Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13 PFE Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13 PFE Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags